GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Additional Paid-In Capital

Heidelberg Pharma AG (XTER:HPHA) Additional Paid-In Capital : €304.78 Mil(As of May. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Additional Paid-In Capital?


Heidelberg Pharma AG's quarterly additional paid-in capital stayed the same from Nov. 2023 (€304.78 Mil) to Feb. 2024 (€304.78 Mil) and stayed the same from Feb. 2024 (€304.78 Mil) to May. 2024 (€304.78 Mil).

Heidelberg Pharma AG's annual additional paid-in capital increased from Nov. 2021 (€238.06 Mil) to Nov. 2022 (€304.74 Mil) and increased from Nov. 2022 (€304.74 Mil) to Nov. 2023 (€304.78 Mil).

Heidelberg Pharma AG Additional Paid-In Capital Historical Data

The historical data trend for Heidelberg Pharma AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Additional Paid-In Capital Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 215.27 227.37 238.06 304.74 304.78

Heidelberg Pharma AG Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 304.77 304.78 304.78 304.78 304.78

Heidelberg Pharma AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Heidelberg Pharma AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Additional Paid-In Capital
Comparable Companies
XTER:MDG1 FRA:D89 FRA:T5O0 OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX BGNE BNTX OCSE:GMAB BMRN UTHR INSM SRPT
Traded in Other Exchanges
HPHA:Germany
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Website
https://www.heidelberg-pharma.com
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG Headlines

No Headlines